Activate your organic marketing with the power of podcasting.

Latest Episodes

The Sales Process: Discovery, Research, Selling

On this episode of Resilience Talk, Paul Spencer unpacks what he has been learning about the sales process through a newer business venture, and why the language your customer uses is often the difference between a yes and a "we already have that." He works through the yes/no/maybe pipeline, how he's using AI to turn customer nuggets into sales assets, and what "sell before you can do" actually looks like in practice.Connect with PaulWebsite: https://www.secondnature.solutions/Subscribe to the newsletter: https://www.secondnature.solutions/joinLinkedIn: https://www.linkedin.com/in/paul-spencer-7252118/Chapters[00:00] Intro: A new business, a new sales reality[00:35] FF&E vs. CapEx: Learning the language that shifted my pitch[08:31] Same business, same costs, same buyer, just a different key[10:18] Yes or no, never maybe: Why maybes drain the pipeline[22:04] Turning customer nuggets into sales assets with Claude[28:40] The S-curve and product-market fit: Why $1M doesn't sell like $20M[37:21] Sell before you can do: Discovery-led selling and the OODA loop[43:22] Predictable, consistent, improving: Closing thoughts

50 Episodes Later: How Travel Tech—and Travel Buddy—Evolved

In this milestone 50th episode of Travel Buddy, Rachel Satow, and Ian Andersen reflect on the journey of the podcast and the evolution of the travel and loyalty industry. From memorable guests and standout episodes to behind-the-scenes insights on how their approach and the industry itself have matured, you’ll hear the inside story of what goes into building a successful travel podcast. The conversation features honest reflections, plenty of humor, and invaluable lessons learned along the way such as game-changing innovations around AI, product development, and partnership building. If you’re curious about what’s next for travel rewards or want a genuine look at the people shaping this space, this episode is not to be missed.Chapters(00:00) Reflections on 50 Episodes and Show Growth(01:00) Evolving Conversations and Deeper Industry Insights(03:00) Hosting Diverse Guests and Partner Highlights(07:00) Platform Innovation and AI Integration(14:00) Maturing Audience and Market Expectations(16:00) Shifting Focus to Internal and External Experts(24:00) Value, Camaraderie, and Looking AheadConnect with SwitchflyWebsite: https://www.switchfly.com/LinkedIn: https://www.linkedin.com/company/switchfly/X: https://twitter.com/switchflyYouTube: https://www.youtube.com/@SwitchflyOfficial

Multi-Platform RCT

In this episode of "In the Interim…", Dr. Scott Berry details the design, execution, and results of the multi-platform randomized clinical trial (mpRCT) pioneered during the COVID-19 pandemic. He describes how REMAP-CAP, ATTACC, and ACTIV-4a—each developed independently—pooled data prospectively for joint analysis to address therapeutic anticoagulation in hospitalized COVID-19 patients. Scott outlines the operational rigor required to harmonize endpoints, establish monthly adaptive analyses, and stratify patients by disease severity and D-dimer level. He examines the unified Bayesian hierarchical modeling approach, dynamic borrowing across strata, and the process for simultaneous DSMB reviews coordinated across all platforms. The mpRCT framework enabled real-time, evidence-based adaptations and rigorous distinction of treatment effect by patient subgroup. Results were incorporated into clinical guidelines because prospectively specified analysis revealed benefit for moderate patients and futility or harm for severe patients—findings that would have been missed by standard post hoc pooling.Key HighlightsIntegration of REMAP-CAP, ATTACC, and ACTIV-4a under a prospectively unified analysis plan.Primary endpoint and stratified patient subgroups defined in advance.Monthly adaptive analyses using a shared Bayesian hierarchical model.Simultaneous oversight by joint statistical and DSMB committees.Superiority of therapeutic anticoagulation in moderate, non-critically ill groups; futility and possible harm in severe patients.mpRCT model established a framework for future global multi-platform trials.For more, visit us at https://www.berryconsultants.com/

Smart Investing in the Age of AI | AWM Insights #252

In this episode of AWM Insights, Chief Investment Officer Justin Dyer and Portfolio Manager Mena Hanna dig into the hype and reality surrounding artificial intelligence and its impact on multi-generational wealth strategies. From the soaring valuations of data centers to the lessons hidden in recent market bubbles, they break down what families should know before investing in AI-driven trends. The conversation brings practical wisdom for long-term investors, highlighting when to tread cautiously, how to diversify effectively, and why the real winners might be the quieter “picks and shovels” businesses. Tune in for a timely, experienced perspective on navigating emerging technology cycles with your legacy in mind.Chapters(00:00) AI Hype and the Hundred-Year Family(01:00) Data Center Demand and Risks(03:31) Valuations, Bubbles, and Investor Caution(06:00) Lessons from High-Profile Speculation(07:52) Venture Capital Strategy and Diversification(10:56) Opportunity in Picks and Shovels Businesses(12:15) Public Markets and Managing ConcentrationConnect with Us• Call or text us: 626-862-0355• Website: https://www.athletefamilyoffice.com/• YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA• LinkedIn: https://www.linkedin.com/company/awmcapital/• Instagram: https://www.instagram.com/awmcapital/• X: https://twitter.com/awmcapital• Facebook: https://www.facebook.com/awmcapital/

Hosts

Josh Alexander

Josh Alexander

Host of The ALX Show
Loren Sanders

Loren Sanders

Host of Conversations WeLearn From
Sean Stowers

Sean Stowers

Host of Conversations WeLearn From
Brandon Giella

Brandon Giella

Host of Redemptive Marketing Podcast